Psychosis during chronic levodopa therapy triggered the new antidepressive drug mirtazapine

被引：43

作者：

Normann, C ^{[1
]}

Hesslinger, B ^{[1
]}

Frauenknecht, S ^{[1
]}

Berger, M ^{[1
]}

Walden, J ^{[1
]}

机构：

[1] Univ Freiburg, Abt Psychiat & Psychotherapie, D-79104 Freiburg, Germany

来源：

PHARMACOPSYCHIATRY | 1997年 / 30卷 / 06期

关键词：

D O I：

10.1055/s-2007-979504

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

We report the case of a patient developing psychosis after the addition of mirtazapine, a novel antidepressant enhancing serotonergic neurotransmission, to a chronic levodopa regimen. There was complete and rapid recovery upon low-dose clozapine treatment. To our knowledge, this is the first published case of a mirtazapine-levodopa interaction and the second case report of a psychosis induced by a serotonergic antidepressant in a patient with Parkinson's disease (PD). This phenomenon might be due to a postsynaptic serotonin receptor supersensitization caused by low central serotonin levels in treated PD.

引用

页码：263 / 265

页数：3

共 29 条

[11]

HADDJERI N, 1995, CLIN PSYCHOPHARM S4, V10, P11

[12]

HEINZ A, 1995, NERVENARZT, V66, P662

[13] PARKINSONISM EXACERBATED BY PAROXETINE [J].

JIMENEZJIMENEZ, FJ ;

TEJEIRO, J ;

MARTINEZJUNQUERO, G ;

CABRERAVALDIVIA, F ;

ALARCON, J ;

GARCIAALBEA, E .

NEUROLOGY, 1994, 44 (12) :2406-2406

[14]

KARABATH M, 1971, EUR J PHARMACOL, V14, P393

[15] Clinical efficacy of mirtazapine: A review of meta-analyses of pooled data [J].

Kasper, S .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :25-35

[16] LEVODOPA-INDUCED DOPAMINE RECEPTOR HYPERSENSITIVITY [J].

KLAWANS, HL ;

GOETZ, C ;

NAUSIEDA, PA ;

WEINER, WJ .

ANNALS OF NEUROLOGY, 1977, 2 (02) :125-129

[17]

LAUTERBACH EC, 1993, AM J PSYCHIAT, V150, P1750

[18]

LEHMANN J, 1973, ACTA MED SCAND, V194, P181

[19] PLASMA CLOZAPINE LEVELS AND THE TREATMENT OF L-DOPA-INDUCED PSYCHOSIS IN PARKINSONS-DISEASE - A HIGH POTENCY EFFECT OF CLOZAPINE [J].

MELTZER, HY ;

KENNEDY, J ;

DAI, J ;

PARSA, M ;

RILEY, D .

NEUROPSYCHOPHARMACOLOGY, 1995, 12 (01) :39-45

[20]

MONASTRUC JL, 1993, LANCET, V341, P555

← 1 2 3 →